These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3670794)

  • 1. Induction of cutaneous plasma cell tumor as a complication of adjuvant immunotherapy with methanol extraction residue of bacillus Calmette-Guérin.
    Suster SM; Ronnen M; Huszar M; Pines A; Schibi-Brilliant G
    Oncology; 1987; 44(5):279-82. PubMed ID: 3670794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
    Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
    Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methanol extraction residue of Bacillus calmette-Guérin in humans.
    Perloff M; Holland JF; Lumb GJ; Bekesi JG
    Cancer Res; 1977 Apr; 37(4):1191-6. PubMed ID: 321117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
    Moff SL; Corey GR; Gottfredsson M
    Clin Infect Dis; 1999 Dec; 29(6):1569-70. PubMed ID: 10585816
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
    Moertel CG; Ritts RE; Schutt AJ; Hahn RG
    Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER).
    Kirkwood JM; Ariyan S; Nordlund JJ; Forget BM
    Cancer; 1982 Oct; 50(7):1299-303. PubMed ID: 7104973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calmette-Guerin bacillus disseminated infection after intravesical instillation].
    Borré S; Brustia D; Rosa F; Brondolo R; Rizzo G; Garavelli PL
    Recenti Prog Med; 2002 Apr; 93(4):247-8. PubMed ID: 11989131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-Guérin.
    Richman SP; Gutterman JU; Hersh EM; Burgess MA; Mavligit GM
    Cancer Treat Rep; 1977; 61(3):471-2. PubMed ID: 872144
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
    Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
    Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular insights into BCG immunotherapy for melanoma.
    Kremenovic M; Schenk M; Lee DJ
    J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic complications of MER immunotherapy of cancer: pulmonary granulomatosis and rash.
    Voith MA; Lichtenfeld KM; Schimpff SC; Wiernik PH
    Cancer; 1979 Feb; 43(2):500-4. PubMed ID: 421177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary abnormalities in patients intravenously receiving the methanol extraction residue (MER) of Bacillus Calmette-Guerin.
    Quesada JR; Libshitz HI; Hersh EM; Gutterman JU
    Cancer; 1980 Mar; 45(6):1340-3. PubMed ID: 7357523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrodermic pustular psoriasis triggered by intravesical bacillus Calmette-Guérin immunotherapy.
    Wee JS; Natkunarajah J; Moosa Y; Marsden RA
    Clin Exp Dermatol; 2012 Jun; 37(4):455-7. PubMed ID: 22582918
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Noor MA; Biyabani SR; Burney IA; Talatia J
    J Pak Med Assoc; 2002 Dec; 52(12):578-80. PubMed ID: 12627909
    [No Abstract]   [Full Text] [Related]  

  • 19. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relapsing Reiter's syndrome after Bacillus Calmette-Guérin immunotherapy for bladder carcinoma].
    Pego JM; Lamas C; Hernández I; Suso J
    Med Clin (Barc); 2003 Sep; 121(9):356-7. PubMed ID: 14499076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.